The global retinal vein occlusion market size is calculated at USD 3.01 billion in 2025 and is forecasted to reach around USD 5.45 billion by 2034, accelerating at a CAGR of 6.81% from 2025 to 2034. The North America market size surpassed USD 1.18 billion in 2024 and is expanding at a notable CAGR of 6.99% during the forecast period. The market sizing and forecasts are revenue-based (USD Million/Billion), with 2024 as the base year.
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
3.1. Market Snapshot
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
5.1. COVID-19 Landscape: Retinal Vein Occlusion Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
8.1. Retinal Vein Occlusion Market, by Disease Type
8.1.1 Central Retinal Vein Occlusion (CRVO)
8.1.1.1. Market Revenue and Forecast
8.1.2. Branch Retinal Vein Occlusion (BRVO)
8.1.2.1. Market Revenue and Forecast
9.1. Retinal Vein Occlusion Market, by Treatment Type
9.1.1. Anti-vascular Endothelial Growth Factor (Anti-VEGF)
9.1.1.1. Market Revenue and Forecast
9.1.2. Corticosteroid Drugs
9.1.2.1. Market Revenue and Forecast
9.1.3. Others
9.1.3.1. Market Revenue and Forecast
10.1. Retinal Vein Occlusion Market, by End-user
10.1.1. Hospital and Clinics
10.1.1.1. Market Revenue and Forecast
10.1.2. Retail Pharmacy
10.1.2.1. Market Revenue and Forecast
10.1.3. Others
10.1.3.1. Market Revenue and Forecast
11.1. North America
11.1.1. Market Revenue and Forecast, by Disease Type
11.1.2. Market Revenue and Forecast, by Treatment Type
11.1.3. Market Revenue and Forecast, by End-user
11.1.4. U.S.
11.1.4.1. Market Revenue and Forecast, by Disease Type
11.1.4.2. Market Revenue and Forecast, by Treatment Type
11.1.4.3. Market Revenue and Forecast, by End-user
11.1.5. Rest of North America
11.1.5.1. Market Revenue and Forecast, by Disease Type
11.1.5.2. Market Revenue and Forecast, by Treatment Type
11.1.5.3. Market Revenue and Forecast, by End-user
11.2. Europe
11.2.1. Market Revenue and Forecast, by Disease Type
11.2.2. Market Revenue and Forecast, by Treatment Type
11.2.3. Market Revenue and Forecast, by End-user
11.2.4. UK
11.2.4.1. Market Revenue and Forecast, by Disease Type
11.2.4.2. Market Revenue and Forecast, by Treatment Type
11.2.4.3. Market Revenue and Forecast, by End-user
11.2.5. Germany
11.2.5.1. Market Revenue and Forecast, by Disease Type
11.2.5.2. Market Revenue and Forecast, by Treatment Type
11.2.5.3. Market Revenue and Forecast, by End-user
11.2.6. France
11.2.6.1. Market Revenue and Forecast, by Disease Type
11.2.6.2. Market Revenue and Forecast, by Treatment Type
11.2.6.3. Market Revenue and Forecast, by End-user
11.2.7. Rest of Europe
11.2.7.1. Market Revenue and Forecast, by Disease Type
11.2.7.2. Market Revenue and Forecast, by Treatment Type
11.2.7.3. Market Revenue and Forecast, by End-user
11.3. APAC
11.3.1. Market Revenue and Forecast, by Disease Type
11.3.2. Market Revenue and Forecast, by Treatment Type
11.3.3. Market Revenue and Forecast, by End-user
11.3.4. India
11.3.4.1. Market Revenue and Forecast, by Disease Type
11.3.4.2. Market Revenue and Forecast, by Treatment Type
11.3.4.3. Market Revenue and Forecast, by End-user
11.3.5. China
11.3.5.1. Market Revenue and Forecast, by Disease Type
11.3.5.2. Market Revenue and Forecast, by Treatment Type
11.3.5.3. Market Revenue and Forecast, by End-user
11.3.6. Japan
11.3.6.1. Market Revenue and Forecast, by Disease Type
11.3.6.2. Market Revenue and Forecast, by Treatment Type
11.3.6.3. Market Revenue and Forecast, by End-user
11.3.7. Rest of APAC
11.3.7.1. Market Revenue and Forecast, by Disease Type
11.3.7.2. Market Revenue and Forecast, by Treatment Type
11.3.7.3. Market Revenue and Forecast, by End-user
11.4. MEA
11.4.1. Market Revenue and Forecast, by Disease Type
11.4.2. Market Revenue and Forecast, by Treatment Type
11.4.3. Market Revenue and Forecast, by End-user
11.4.4. GCC
11.4.4.1. Market Revenue and Forecast, by Disease Type
11.4.4.2. Market Revenue and Forecast, by Treatment Type
11.4.4.3. Market Revenue and Forecast, by End-user
11.4.5. North Africa
11.4.5.1. Market Revenue and Forecast, by Disease Type
11.4.5.2. Market Revenue and Forecast, by Treatment Type
11.4.5.3. Market Revenue and Forecast, by End-user
11.4.6. South Africa
11.4.6.1. Market Revenue and Forecast, by Disease Type
11.4.6.2. Market Revenue and Forecast, by Treatment Type
11.4.6.3. Market Revenue and Forecast, by End-user
11.4.7. Rest of MEA
11.4.7.1. Market Revenue and Forecast, by Disease Type
11.4.7.2. Market Revenue and Forecast, by Treatment Type
11.4.7.3. Market Revenue and Forecast, by End-user
11.5. Latin America
11.5.1. Market Revenue and Forecast, by Disease Type
11.5.2. Market Revenue and Forecast, by Treatment Type
11.5.3. Market Revenue and Forecast, by End-user
11.5.4. Brazil
11.5.4.1. Market Revenue and Forecast, by Disease Type
11.5.4.2. Market Revenue and Forecast, by Treatment Type
11.5.4.3. Market Revenue and Forecast, by End-user
11.5.5. Rest of LATAM
11.5.5.1. Market Revenue and Forecast, by Disease Type
11.5.5.2. Market Revenue and Forecast, by Treatment Type
11.5.5.3. Market Revenue and Forecast, by End-user
12.1. Alcon
12.1.1. Company Overview
12.1.2. Product Offerings
12.1.3. Financial Performance
12.1.4. Recent Initiatives
12.2. Pfizer Inc.
12.2.1. Company Overview
12.2.2. Product Offerings
12.2.3. Financial Performance
12.2.4. Recent Initiatives
12.3. Genentech
12.3.1. Company Overview
12.3.2. Product Offerings
12.3.3. Financial Performance
12.3.4. Recent Initiatives
12.4. Regeneron Pharmaceuticals Inc.
12.4.1. Company Overview
12.4.2. Product Offerings
12.4.3. Financial Performance
12.4.4. Recent Initiatives
12.5. Allergan plc
12.5.1. Company Overview
12.5.2. Product Offerings
12.5.3. Financial Performance
12.5.4. Recent Initiatives
12.6. Johnson & Johnson
12.6.1. Company Overview
12.6.2. Product Offerings
12.6.3. Financial Performance
12.6.4. Recent Initiatives
12.7. F. Hoffmann-La Roche Ltd.
12.7.1. Company Overview
12.7.2. Product Offerings
12.7.3. Financial Performance
12.7.4. Recent Initiatives
12.8. Taiwan Liposome Company, Ltd.
12.8.1. Company Overview
12.8.2. Product Offerings
12.8.3. Financial Performance
12.8.4. Recent Initiatives
12.9. AbbVie Inc.
12.9.1. Company Overview
12.9.2. Product Offerings
12.9.3. Financial Performance
12.9.4. Recent Initiatives
12.10. Chugai Pharmaceutical Co., Ltd.
12.10.1. Company Overview
12.10.2. Product Offerings
12.10.3. Financial Performance
12.10.4. Recent Initiatives
13.1. Primary Research
13.2. Secondary Research
13.3. Assumptions
14.1. About Us
14.2. Glossary of Terms
For questions or customization requests, please reach out to us at sales@precedenceresearch.com
Plan your call and get expert insights!
Schedule a Meeting
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client
Report Description
Get a Sample